$162.25
2.361.47%
Last update: Nov 4, 3:33 PM
Alnylam Pharmaceuticals Inc
ALNYNASDAQ
Alnylam Pharmaceuticals (ALNY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Alnylam Pharmaceuticals (ALNY) last issued guidance on October 29, 2026 for fiscal year 2026. The company guided revenue in the range of $5.28B - $5.72B for the period.
Compared to prior guidance, Alnylam Pharmaceuticals maintained its revenue forecast from a prior range of $5.28B - $5.72B.
Alnylam Pharmaceuticals has issued 16 guidance updates between February 23, 2023 and October 29, 2026. During this period, the company raised its outlook 6 times, reflecting management's growing confidence in business performance.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.09 | $2.00 | $1.36 | $1.20 |
| Actual | $16.26 | $1.84 | $1.99 | $1.25 |
| Surprise | +678.0% | -8.00% | +46.3% | +4.17% |
| Revenue | ||||
| Estimate | $1.43B | $1.32B | $1.12B | $1.15B |
| Actual | $1.46B | $1.29B | $1.17B | $1.10B |
| Surprise | +1.74% | -2.02% | +4.26% | -4.64% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.23 | $2.57 | $2.36 | $2.61 |
| Revenue | ||||
| Consensus | $1.53B | $1.56B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $16.26 | $2.09 | 678.0 % |
| Q2 | Jul 30, 2026 | $1.84 | $2.00 | -8.00 % |
| Q1 | Apr 30, 2026 | $1.99 | $1.36 | 46.3 % |
| Q4 | Feb 12, 2026 | $1.25 | $1.20 | 4.17 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $1.46B | $1.43B | 1.74 % |
| Q2 | Jul 30, 2026 | $1.29B | $1.32B | -2.02 % |
| Q1 | Apr 30, 2026 | $1.17B | $1.12B | 4.26 % |
| Q4 | Feb 12, 2026 | $1.10B | $1.15B | -4.64 % |
